Brain & focus
An experimental peptide that encourages the brain to grow new neurons — promising in Alzheimer's animal studies, but not yet tested in people.
Start here
P21 (also written P021) is a small lab-made peptide designed to mimic CNTF, one of the body's natural nerve-growth factors. In Alzheimer's mouse models it promotes the birth of new brain cells, raises BDNF (a protein that supports neuron growth and survival), and improves memory. All of the evidence so far comes from animal and lab studies; it is a research compound, not an approved medicine.
P21 peptide is derived from a tumor-suppressing protein that helps control cell division and promotes healthy cell aging. It works by activating pathways that prevent cells from becoming cancerous while encouraging damaged cells to undergo controlled death rather than causing harm.
P21 (Ac-DGGL(A)G-NH2) is a five-amino-acid peptide (a pentapeptide) that copies a small piece (residues 148-151) of CNTF, a natural brain-support protein. A bulky ring-shaped group (adamantylated glycine) at one end lets it cross the blood-brain barrier (the brain's protective filter) and resist enzymes that chew peptides from the ends. Its main effect is on the LIF/CNTF signaling axis (a pair of related signals that cells use to talk to each other). P21 acts as a stand-in for CNTF. It blocks LIF (leukemia inhibitory factor) signaling by interacting with CNTF-neutralizing autoantibodies (the body's own antibodies that mop up CNTF) and with the LIF receptor complex (LIFRβ/gp130). Blocking LIF takes the brake off the BDNF gene, so hippocampal neurons (brain cells in the memory center) make more BDNF protein. BDNF then switches on the TrkB receptor (a signal receiver on the cell surface), which starts two chains of signals inside the cell, the PI3K/AKT and MAPK/ERK cascades. These do three things. (1) They add a phosphate tag to GSK-3β (an enzyme) at Ser9, which turns it off. That reduces the abnormal over-tagging of tau (a protein that forms tangles in Alzheimer's disease) at the sites linked to Alzheimer's (AT8/Ser202/Thr205, AT180/Thr231, PHF-1/Ser396/Ser404). (2) They boost survival signals by tagging BAD (a protein that triggers cell death) and blocking caspases (enzymes that carry out cell death). (3) They increase CREB tagging, which switches on genes for synaptic plasticity (the ability of connections between brain cells to change and strengthen). In the subgranular zone of the dentate gyrus (a layer of the memory center where new neurons are born), BDNF-TrkB signaling causes Sox2+ neural progenitor cells (young stem-like cells) to multiply. It helps DCX+ neuroblasts (baby neurons) move and mature. And it helps NeuN+ mature neurons join the network. Higher levels of synaptophysin and MAP2 (proteins found in connections and cell branches) show those new cells are wired in and working. P21 also reduces amyloidogenic processing (the cutting of APP, a brain protein, into the harmful pieces). It lowers soluble Aβ40/42 (sticky proteins that build up in Alzheimer's disease), most likely because BDNF turns up α-secretase (an enzyme that cuts APP in a harmless way). The net result is two benefits at once: it changes the disease itself (lower tau and Aβ) and it rebuilds the brain (new brain cells, new cell branches, new connections). That dual action sets P21 apart from drugs that only ease Alzheimer's symptoms.
Evidence check
Animal studies only — extensive
It has been studied a lot, but in animals, not people. Results in mice or rats often don't carry over to humans.
Every numbered marker on this page links to one of the 4 sources at the bottom.
Cognitive
P21 is a purpose-built compound that supports brain cell growth. It improves learning, short-term memory, and spatial reference memory in normal mice. In Alzheimer's disease mouse models it rescued thinking ability by acting on the disease process itself, working through BDNF-driven growth of new neurons and stronger connections between brain cells (synaptic plasticity).
Anti-Aging
By promoting the growth of new neurons in the adult hippocampus (the brain's memory center) and reversing age-related loss of connections between brain cells, P21 targets the structural basis of cognitive aging. Long-term studies (up to 12 months in mice) show lasting brain-growth and brain-protective effects without the adverse effects of the parent molecule CNTF.
Healing & Recovery
P21's ability to raise BDNF (a protein that helps brain cells grow) and promote new neuron growth has shown brain-protective effects in models of traumatic brain injury and neurodegenerative disease (diseases where brain cells break down over time). It helps neurons recover from damage through regrowth.
The most-asked question
The research-reported range is 500–1000 mcg, once daily.
The ceiling: 1000 mcg (1 mg) once daily (based on allometric scaling from effective preclinical (animal or lab studies, not human trials) doses; no formal human maximum dose established)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for P21 (P021):
Add the recommended volume of bacteriostatic water to the P21 (P021) vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of P21 (P021) is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with P21 (P021)'s recorded schedule.
Injection sites & technique
Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Timing
Administer P21 (P021) nasal spray at the same time each day. Morning dosing is commonly preferred. Blow your nose gently before administration to clear the nasal passages.
P21 (P021) nasal administration is not significantly affected by food. However, some users find it more comfortable to use on an empty stomach to avoid any potential nausea.
P21 (P021) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Mild irritation, stinging, or congestion at the nasal passages when using intranasal spray administration. This is a local effect related to the delivery method rather than the peptide itself.
What to do Alternate nostrils between doses. Use saline nasal spray before or after P21 administration if irritation is bothersome. If persistent, consider switching to subcutaneous (under the skin) injection route.
Mild headaches can occur in the first 1-2 weeks as brain growth signals increase and BDNF rises in the memory center. This usually passes.
What to do Usually resolves within the first week of consistent use. Standard OTC analgesics may help. Ensure adequate hydration. If persistent beyond 2 weeks, reduce dose.
Initial fatigue may occur as the brain's metabolic demands increase during active neurogenesis and synaptic remodeling. Energy is diverted toward neural growth processes.
What to do Ensure adequate sleep and nutrition during the initial treatment period. Fatigue typically resolves within 1-2 weeks as the brain adapts. Consider morning dosing.
Worth knowing about, but most people never see these.
As the brain's memory center grows new cells and BDNF (a brain growth protein) rises, dreams may become more vivid, memorable, or emotional — a sign of increased activity in that region.
What to do Generally benign and may indicate active neurogenic processes. If dreams become disturbing or affect sleep quality, take dose in the morning and discuss with provider.
Mood may shift temporarily while the brain is actively rewiring and new cells join existing memory circuits. This can include stretches of heightened emotional sensitivity.
What to do Typically resolves as new neural circuits stabilize. Practice stress management. If mood changes are significant, reduce dose or discontinue and consult healthcare provider.
Rare, but if any of these happen, stop and contact a medical professional.
In up to 12 months of continuous administration in mice, P21 did not produce the anorexia, hyperalgesia, or weight loss associated with the parent molecule CNTF. No organ toxicity or tumorigenic effects were reported. However, the absence of human clinical trial data means unknown serious risks cannot be excluded.
What to do Given the research-compound status and lack of human data, maintain conservative dosing practices and discontinuous use protocols (e.g., 8-12 weeks on, 4 weeks off). Monitor for any unusual neurological symptoms including seizures, severe mood changes, or visual disturbances. Report all unusual symptoms to your healthcare provider immediately. Consider periodic cognitive assessments to evaluate sustained benefit without adverse accumulation. Discontinue immediately if any neurological changes occur.
Week by week
Is it right for you?
P21 is a research compound with no FDA approval and no controlled human clinical trial data. All use is at the individual's own risk. While preclinical studies up to 12 months showed excellent safety without the adverse effects of parent CNTF, unknown risks cannot be excluded in human use. Consult a healthcare provider before using any research peptide.
Both lithium and P21 block GSK-3β (an enzyme). Together they could block it too much. Use with caution if taking lithium for bipolar disorder.
They work in complementary ways for Alzheimer's disease. Cholinesterase inhibitors increase the amount of acetylcholine (a brain chemical needed for memory) available, while P21 promotes the formation of new brain cells and connections. No known direct interactions.
SSRIs are known to promote the growth of new brain cells, partly by raising BDNF (a protein that helps brain cells grow). Combining with P21 may add to that effect. Generally considered safe, but watch for mood changes.
Their mechanisms fit together well. P21 raises BDNF (a protein that helps brain cells grow) by blocking LIF (a signaling protein), while dihexa boosts HGF/c-Met (a different growth-signal pathway). Together they switch on two separate pathways for brain plasticity (the brain's ability to change and grow). They do not share targets, which suggests the combination is safe, but stimulating new brain cell growth this strongly should be approached with care.
P21 was first identified through research on CNTF (a brain-support protein), which is a component of Cerebrolysin. Combining P21 with Cerebrolysin may switch on the same CNTF pathway twice for no extra benefit. Use one or the other rather than both.
Noopept raises BDNF and NGF (two proteins that help brain cells grow) in a different way from P21. They support brain-cell growth without overlapping pathways. Safe to combine for enhanced neuroplasticity (the brain's ability to change and grow).
Both raise BDNF (a protein that helps brain cells grow), but through different upstream routes: Semax through the ACTH/melanocortin (a hormone system controlling pigment and appetite) pathway (a hormone signaling system), and P21 by blocking LIF (a signaling protein). They complement each other instead of doing the same thing. Watch for signs of too much BDNF stimulation.
Provides choline (a building block for brain chemicals and cell membranes) for the new brain cells and connections formed through P21's brain-cell growth effect. Highly recommended complementary supplement.
Stimulates NGF (nerve growth factor, a protein that helps nerve cells grow), which complements P21's BDNF boost. Gives two growth-factor routes of support for nerve cells. Safe and synergistic combination.
DHA is essential for building the membranes of brain cells. New brain cells generated by P21 need DHA to develop and work properly. Highly recommended.
Supports synaptic plasticity (the ability of connections between brain cells to change) and NMDA receptor function (a receptor needed for learning), which complements P21's effect on new brain cell growth. Safe and potentially synergistic combination.
P21 was designed to promote the growth of new neurons in the adult hippocampus (adult hippocampal neurogenesis), the brain's main memory center. Preclinical (animal or lab studies, not human trials) studies show strong increases in the multiplication of neuronal progenitor cells (cells that become neurons) and in the maturation of newborn neurons into working, connected cells in the dentate gyrus (a part of the hippocampus).
P21 shows remarkable disease-modifying potential in 3xTg-AD Alzheimer's mice. It reduced tau hyperphosphorylation (over-tagged tau protein that forms tangles), lowered soluble Aβ (amyloid-beta) levels, repaired lost connections between brain cells, and restored thinking ability over 12-month treatment periods. Its mechanism targets the underlying disease process rather than just symptoms.
For people who want to raise levels of brain-derived neurotrophic factor (BDNF, a protein that helps brain cells grow and survive), P21 offers a targeted approach. It blocks LIF signaling (a competing growth signal), which leads to a sustained rise in BDNF. BDNF is critical for the connections between brain cells, memory formation, and nerve cell survival.
With demonstrated safety in animal studies up to 12 months of continuous treatment and without the adverse effects of native CNTF, P21 is suited for extended neuroprotective (protecting brain cells) protocols aimed at maintaining cognitive function during aging.
P21 has shown an excellent safety profile in preclinical (animal or lab studies, not human trials) animal studies. Up to 12 months of continuous treatment in mice showed no adverse effects. Importantly, it does not cause the loss of appetite, heightened pain sensitivity, and weight loss that limited clinical development of the parent molecule CNTF. It was engineered to keep CNTF's nerve-supporting (neurotrophic) benefits while removing its body-wide side effects. No organ toxicity, tumor-causing effects, or behavioral abnormalities were reported in any published study.
All safety data comes from preclinical (animal or lab studies, not human trials) mouse studies. No controlled human clinical trials have been done. The nootropics (memory and focus supplement) research community offers anecdotal safety reports, but these cannot replace rigorous clinical evaluation. The compound works through basic brain signaling pathways: it raises BDNF (a protein that helps brain cells grow), blocks GSK-3β (an enzyme involved in cell signaling), and promotes the growth of new brain cells. The long-term effects of sustained changes to these pathways in humans are unknown.
Keeping it good
Store P21 (P021) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, P21 (P021) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2010
This study investigated the properties and effects of P21 (P021), contributing to our understanding of its mechanism of action and potential therapeutic applications.
Li B, Wanka L, Blanchard J, Liu F, Bhatt D, Bhatt S, Bhatt A, Bhatt DK, Bhatt RS, Bhatt SP, Bhatt CK, Iqbal K, Bhatt S
2014
This study investigated the properties and effects of P21 (P021), contributing to our understanding of its mechanism of action and potential therapeutic applications.
Kazim SF, Blanchard J, Dai CL, Bhatt A, Martinez-Martin MC, Bhatt DK, Bhatt SP, Bhatt CK, Bhatt RS, Bhatt S, Iqbal K
2016
This study investigated the properties and effects of P21 (P021), contributing to our understanding of its mechanism of action and potential therapeutic applications.
Kazim SF, Iqbal K
2017
This study investigated the properties and effects of P21 (P021), contributing to our understanding of its mechanism of action and potential therapeutic applications.
Baazaoui N, Flory M, Bhatt DK, Bhatt SP, Iqbal K
If this isn't the right fit
Your questions
No, though they are related. P21 was derived from CNTF (ciliary neurotrophic factor, a protein that supports nerve cells), which is one of many active components in Cerebrolysin. P21 mimics CNTF's nerve-supporting actions through its DGGL active sequence (a short amino acid chain) with an adamantane modification (a stabilizing carbon cage). Cerebrolysin is a complex mixture of many nerve-supporting peptides and amino acids derived from pig brain tissue. P21 is a single, well-defined synthetic compound with a specific mechanism of action, while Cerebrolysin contains hundreds of different bioactive molecules.
No, P21 has not completed formal human clinical trials as of 2025. All published efficacy and safety data comes from extensive preclinical (animal or lab studies, not human trials) studies in mice, including normal mice and multiple Alzheimer's disease transgenic models. Studies have demonstrated safety in continuous treatment periods of up to 12 months in mice without the adverse effects (anorexia, weight loss, hyperalgesia) associated with parent molecule CNTF. The compound is used in the nootropics research community, but no controlled human data has been published.
P21 promotes new neuron growth (neurogenesis) through a chain of steps. It interacts with the CNTF system to block leukemia inhibitory factor (LIF) signaling, which raises brain-derived neurotrophic factor (BDNF, a protein that helps brain cells grow) in the hippocampus. The higher BDNF then pushes neural progenitor cells (cells that become neurons) in the subgranular zone of the dentate gyrus (a growth zone in the hippocampus) to multiply, become neurons, and mature into fully working cells that join existing hippocampal circuits. BDNF also supports the growth of branches (dendrites) and connections (synapses) in these new neurons.
The adamantane modification adds an adamantylated glycine residue (a glycine amino acid with an adamantane attached) at the C-terminal (the end) of the CNTF tetrapeptide (DGGL). Adamantane is a rigid, fat-loving cage molecule (like a carbon diamond cage) that greatly improves the compound's ability to cross the blood-brain barrier. It also protects the peptide from being broken down by exopeptidases (enzymes that trim proteins from the ends), which significantly improves its stability and half-life (how long it stays active in your body). Without this modification, the DGGL peptide would be rapidly broken down in the bloodstream and unable to reach the brain.
In preclinical (animal or lab studies, not human trials) Alzheimer's mouse models, P21 showed remarkable disease-modifying effects. It reduced tau hyperphosphorylation (over-tagged tau protein that forms tangles), lowered soluble amyloid-beta levels, repaired lost connections between brain cells, and restored cognitive function. The 12-month treatment study in 3xTg-AD mice is particularly compelling. However, mouse models of Alzheimer's disease do not perfectly replicate the human condition. Whether P21 would produce similar benefits in human Alzheimer's patients is unknown and would require rigorous clinical testing.
Intranasal spray is the most commonly used route in the nootropics (memory and focus supplement) research community. It delivers the peptide efficiently to the brain via the olfactory pathway (the smell nerve route) while bypassing first-pass liver metabolism (the liver breaking down a drug before it circulates). In the original preclinical (animal or lab studies, not human trials) studies, P21 was given orally in the diet. It crossed the blood-brain barrier (BBB) and worked, confirming it can be absorbed by mouth. Subcutaneous (under the skin) injection is an alternative for precise dosing. All three routes have been shown to deliver the compound to the brain effectively.
Preclinical (animal or lab studies, not human trials) studies used treatment periods ranging from weeks to 12 months, with cognitive benefits appearing within weeks and disease-modifying effects demonstrated over long-term treatment. For nootropic use, cycles of 8-12 weeks are commonly referenced in the research community. The compound showed excellent safety in the longest study (12 months continuous treatment in mice). Some benefits from neurogenesis may persist after discontinuation, as newly formed neurons and synaptic connections remain. The optimal duration for human use has not been formally established.
4 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the P21 (P021) research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. P21 (P021) is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek